Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONSTANCE study of faricimab up to every 24 weeks in neovascular age-related macular degeneration
2024-517545-13-00Phase 4Authorised
- Sponsor
- Roche
- Start
- Jun 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 4, randomised, open-label trial of faricimab in exudative macular degeneration (2 arms), sponsored by Roche. Primary endpoint: Change from baseline in best-corrected visual acuity score. Planned start Jun 2025; status: authorised.
02
Drugs
faricimab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on 2024-517545-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517545-13-00.